Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New blood test could spot type 1 diabetes before symptoms strike

NCT ID NCT04164966

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks for tiny particles in the blood, called exosomes, that might signal the start of type 1 diabetes. Researchers will compare children recently diagnosed with type 1 diabetes to healthy children, all aged 12 to 18. The goal is to find a better way to catch the disease early and track how it progresses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to diagnose type 1 diabetes earlier, potentially before symptoms appear.
What could go wrong
This is a small, early-stage study with only 28 participants, so results may not apply to everyone. The biomarkers being studied are experimental and may not prove reliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

28 people

The number who actually took part.

Started

Nov 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Males and females 12-18 years of age with a diagnosis of type 1 diabetes within the past 3 months or those who do not have diabetes.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Type 1 Diabetes (T1D) 1. Age 12-18 years inclusive 2. Diagnosis of T1D according to American Diabetes Association (ADA) criteria with an acute onset and presence of islet associated autoantibody by history. 3. T1D duration of ≤ 3 months from the diagnosis Healthy Normal Volunteers (HNV) 1. Age 12-18 years inclusive 2. No personal history of diabetes according to ADA criteria 3. No history of T1D or insulin treated diabetes in first degree relatives (FDR) Exclusion Criteria: Acute or chronic medical conditions or medication that would contraindicate the participation in the research testing or could potentially affect metabolic and immune function including, but not limited to: 1. History of type 2 diabetes 2. Suspicion of non-type 1 diabetes (e.g. maturity onset diabetes of the young or secondary diabetes) 3. History of thyroid dysfunction in which the participant has not been on a stable dose (at least 6 weeks prior to enrollment) of thyroid replacement medication or antithyroid drugs. 4. History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable). 5. History of organ transplant 6. History of HIV, active Hepatitis B or C, or Tuberculosis 7. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection 8. Psychiatric disease prohibiting adherence to study protocol 9. Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs. 10. Use of any other medications known to influence glucose, fat and/or energy metabolism within the last 3 months (e.g., growth hormone therapy, glucocorticoids \[steroids\], prescribed medications for weight loss, etc.) 11. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AdventHealth Translational Research Institute

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.